BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer

SABCS 2025: Latest developments in multigene testing in early breast cancer

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma

MRD validated as a surrogate endpoint for survival in AML

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Exploring genomic insights in acute lymphoblastic leukaemia treatment